Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on Oct...
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2016-06-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 386
- Registration Number
- NCT00760344
A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.
- Conditions
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 666
- Registration Number
- NCT00754988
Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients
- Conditions
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 515
- Registration Number
- NCT00751114
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2008-09-09
- Last Posted Date
- 2014-06-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 495
- Registration Number
- NCT00749190
- Locations
- 🇷🇴
1245.10.40002 Boehringer Ingelheim Investigational Site, Bucharest, Romania
🇷🇴1245.10.40004 Boehringer Ingelheim Investigational Site, Galati, Romania
🇺🇦1245.10.38001 Boehringer Ingelheim Investigational Site, Vinnitsa, Ukraine
How Improvement in Control of Diabetes Influences the Production of a Hormone Produced in the Gut Which Improves the Release and Action of Insulin.
- Conditions
- Interventions
- First Posted Date
- 2008-09-05
- Last Posted Date
- 2012-12-05
- Lead Sponsor
- The Royal Bournemouth Hospital
- Target Recruit Count
- 74
- Registration Number
- NCT00747383
- Locations
- 🇬🇧
Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom
Sitagliptin in Renal Transplant Recipients
- First Posted Date
- 2008-08-25
- Last Posted Date
- 2012-09-25
- Lead Sponsor
- University of Oslo School of Pharmacy
- Target Recruit Count
- 25
- Registration Number
- NCT00740363
- Locations
- 🇳🇴
Rikshospitalet Medical Center, Oslo, Norway
A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin
- Conditions
- Interventions
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2015-04-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1202
- Registration Number
- NCT00734474
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yung-Kang, Tainan, Taiwan
Bone Turnover in Type 2 Diabetes Patients
- First Posted Date
- 2008-08-11
- Last Posted Date
- 2010-06-28
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 20
- Registration Number
- NCT00732121
- Locations
- 🇺🇸
University of Vermont, South Burlington, Vermont, United States
Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione
- Conditions
- Interventions
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 83
- Registration Number
- NCT00729326
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 121
- Registration Number
- NCT00716092
- Locations
- 🇩🇪
1218.37.49003 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪1218.37.49002 Boehringer Ingelheim Investigational Site, Mainz, Germany
🇩🇪1218.37.49001 Boehringer Ingelheim Investigational Site, Neuss, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.